Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Big Pharma is facing a looming $236 Billion patent cliff

<< Previous

Bullboard Posts

Next >>

Comment by Normandt1965on Jun 08, 2022 2:36pm

135 Views

Post# 34741176

RE:RE:RE:RE:RE:RE:RE:Big Pharma is facing a looming $236 Billion patent cliff

Which ones we lost from my quotes to yours, I'm curious to know. I think you just try to make people insecure about the future of Oncy. Why they should extend the patent right now since the main ones are good until 2028. You suggest the trials in progress will not be finished another way sow doubt. I know your way very well .

<< Previous

Bullboard Posts

Next >>

Options trading in a volatile macro environment